Engineering humanized antibody framework sequences for optimal site-specific conjugation of cytotoxins. Issue 6 (18th August 2017)

• Record Type: Journal Article
• Authors: Spidel, Jared L.; Albone, Earl F.; Cheng, Xin; Vaessen, Benjamin; Jacob, Sara; Milinichik, Andrew Z.; Verdi, Arielle; Kline, J. Bradford; Grasso, Luigi
• Is Part Of: MAbs. Volume 9:Issue 6(2017)
• Page Start: 907
• Page End: 915
• Publication Date: 2017-08-18
• Subjects: Antibody -- antibody-drug conjugate -- cysteine -- framework -- humanization -- immunoconjugate -- rabbit -- site-specific conjugation -- variable; Monoclonal antibodies -- Therapeutic use -- Periodicals; Monoclonal antibodies -- Periodicals; Antibodies, Monoclonal -- Periodicals; 616.0798
• DOI: 10.1080/19420862.2017.1330734
• Languages: English
• ISSNs: 1942-0862

Abstract

ABSTRACT: The prevailing techniques used to generate antibody-drug conjugates (ADCs) involve random conjugation of the linker-drug to multiple lysines or cysteines in the antibody. Engineering natural and non-natural amino acids into an antibody has been demonstrated to be an effective strategy to produce homogeneous ADC products with defined drug-to-antibody ratios. We recently reported an efficient residue-specific conjugation technology (RESPECT) where thiol-reactive payloads can be efficiently conjugated to a native unpaired cysteine in position 80 (C80) of rabbit light chains. Deimmunizing the rabbit variable domains through humanization is necessary to reduce the risk of anti-drug antibody responses in patients. However, we found that first-generation humanized RESPECT ADCs showed high levels of aggregation and low conjugation efficiency. We correlated these negative properties to the phenylalanine at position 83 present in most human variable kappa frameworks. When position 83 was substituted with selected amino acids, conjugation was restored and aggregation was reduced to levels similar to the chimeric ADC. This engineering strategy allows for development of second-generation humanized RESPECT ADCs with desirable biopharmaceutical properties.